Endocrine Abstracts

Introduction: The NETTER 1 trial resulted in markedly longer progression-free survival (PFS), with preliminary evidence of an overall survival benefit. We report the results of PFS and safety of (177Lu)-DOTATATE in patients treated in our hospital between 2014 and 2016.

Methods: Transversal and descriptive study of seven patients with advanced, progressive, somatostatin receptor-positive tumors who had received previous treatments. All of them were treated in progressive disease with (177Lu)-DOTATATE. Results are expressed in average (S.D.) or percentage(%). SPSS version 2.2 was used for statistical analysis.

Results: 71.4% (5) were women, with an average age of 46.4 (16.2). Histological classification was: 4 (57%) well-moderate differentiated neuroendocrine tumors (three pancreatic, one ileal), 2 (28.6%) paragangliomas and 1 (14.3%) follicular thyroid carcinoma. At the time of administration of (177Lu)-DOTATATE, all tumors were in metastatic stage. The localization of the metastasis was: bone 85.7% (6), liver 57.1% (4), lymph nodes 42.8% (3) and lungs 14.3% (1). All patients had received previous treatments: two underwent surgery exclusively, five of them several systemic therapies: one with somatostatin analogues (SA) and surgery, two only SA, one surgery, SA, temsirolimus and sunitinib, and one patient with diagnosis of metastatic follicular thyroid carcinoma, received: surgery, radioiodine, sorafenib, sunitinib, everolimus, adryamicine, and SA. 177Lu-DOTATE was infused every eight weeks in four doses, except in two patients who have received only three. At the data-cutoff date PFS was of 20.29 (7.13) months. Two patients had adverse events related to the treatment: one hematologic events (mild-moderate thrombocytopenia and anemia), and one self-limited nausea and vomiting. Death occurred in one patient after 15 months of stable disease.

Conclusions: In real world practice treatment with (177Lu)-DOTATATE not only shows benefit in advanced intestinal NETS but also in other patients with metastatic disease, previous treatments, and positive somatostatin-receptor expression it seems to have favorable results attending to PFS and safety.